You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 6,719,981

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,719,981

Title:	Stable, attenuated rabies virus mutants and live vaccines thereof
Abstract:	The present invention relates to recombinant rabies virus mutants comprising a mutation in the viral genome, whereby said mutation comprises at least a substitution of the Arg.sub.333 codon in the gene encoding the G protein with a codon that differs by three nucleotides from said Arg.sub.333 codon. These rabies virus mutants have a glycoprotein G that comprises an amino acid at position 333 which is encoded by a codon that differs by all three nucleotides from the Arg codon in amino acid position 333 in the glycoprotein of the parental virus. Said recombinant rabies virus mutants are stable and non-pathogenic in immune competent animals and are suitable for use in a live, attenuated anti-rabis vaccine.
Inventor(s):	Mebatsion; Teshome T (Boxmeer, NL), Conzelmann; Karl Klaus (Neuried, DE)
Assignee:	Akzo Nobel N.V. (Arnhem, NL)
Application Number:	09/856,653
Patent Claims:	1. A recombinant rabies virus mutant of a SAD strain, comprising: a mutation in the G protein of the viral genome, wherein said mutation comprises a substitution of a AGA codon encoding Arg.sub.333 with a GAC codon, wherein said mutant is SAD D29. 2. A recombinant rabies virus mutant of a SAD strain, comprising: a mutation in the G protein of the viral genome, wherein said mutation comprises a substitution of a AGA codon encoding Arg.sub.333 with a CAC codon, wherein said mutant is SAD H31. 3. A live attenuated anti-rabies vaccine, comprising: the recombinant rabies virus mutant according to claim 1, and a pharmaceutically acceptable carrier. 4. A live attenuated anti-rabies vaccine, comprising: the recombinant rabies virus mutant according to claim 2, and a pharmaceutically acceptable carrier.

Details for Patent 6,719,981

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bavarian Nordic A/s	RABAVERT	rabies vaccine	For Injection	103334	10/20/1997	⤷ Try a Trial	2018-11-27
Sanofi Pasteur Sa	IMOVAX RABIES	rabies vaccine	For Injection	103931	02/04/2000	⤷ Try a Trial	2018-11-27
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.